C-cell cancer - Prevention and treatment

Langenbeck's Archives of Surgery

Volumn 384, Issue 1, 1999, Pages 16-23

  Gimm, O ^a   Dralle, H ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

C cell cancer; Medullary thyroid carcinoma; Prevention; Treatment

Indexed keywords

FAMILIAL CANCER; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; PRIORITY JOURNAL; REVIEW; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

CARCINOMA, MEDULLARY; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; THYROID NEOPLASMS;

EID: 0032929899     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004230050168     Document Type: Review

References (69)

1. Jaquet A.I (1906) Ein Fall von metastasierenden Amyloidtumoren (Lymphosarcoma). Virchows Arch 185:251
2. Hazard JB, Hawk WA, Crile G (1959) Medullary (solid) carcinoma of the thyroid - a clinicopathologic entity. J Clin Endocrinol Metab 19: 152-161
3. Williams ED, Brown CL, Doniach I (1966) Pathological and clinical findings in a series of 67 cases of medullary carcinoma of the thyroid. J Clin Pathol 19: 103-113
4. Melvin KE, Tashjian AH, Jr. (1968) The syndrome of excessive thyrocalcitonin produced by medullary carcinoma of the thyroid. Proc Natl Acad Sci U S A 59: 1216-1222
5. Meyer JS, Abdel-Bari W (1968) Granules and thyrocalcitonin-like activity in medullary carcinoma ot the thyroid gland. N Engl J Med 278:523-529
6. Wells SA, Jr., Baylin SB, Linehan WM, Farrell RE, Cox EB, Cooper CW (1978) Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. Ann Surg 188: 139-141
7. DeCourcy JL, DeCourcy CB (1952) Pheochromocytoma and the general practitioner. Barclay Newman, Cincinnatti
8. Williams ED (1965) A review of 17 cases of carcinoma of the thyroid and phaechromocytoma. J Clin Pathol 18:288-292
9. Schimke RN, Hartmann WH( 1965) Familial amyloid-producing medullary thyroid carcinoma and pheochromocytoma. A distinct genetic entity. Ann Intern Med 63: 1027-1039
10. Steiner AL, Goodman AD, Powers SR (1968) Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2. Medicine (Baltimore) 47:371-409
11. Simpson NE, Kidd KK, Goodfellow PJ, McDermid H, Myers S, Kidd JR, Jackson CE, Duncan AM, Farrer LA, Brasch K, et al. (1987) Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature 328:528-530
12. Mathew CG, Chin KS, Easton DF, Thorpe K, Carter C, Liou GI, Fong SL, Bridges CD, Haak H, Kruseman AC, et al. (1987) A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 328:527-528
13. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, et al. (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460
14. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA, Jr. (1993) Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856
15. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JW, van Amstel HK, Romeo G, et al. (1994) A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma (comments). Nature 367:375-376
16. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GF, Jackson CE, Tunnacliffe A, et al. (1994) Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3:237-241 (erratum 3:686)
17. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA, Jr., Goodfellow PJ, Donis-Keller H (1994) Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 91: 1579-1583
18. Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JB, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H, et al. (1994) Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 6:70-74
19. Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield MD, Ponder BA (1995) A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 10:509-513
20. Bolino A, Schuffenecker I, Luo Y, Seri M, Silengo M, Tocco T, Chabrier G, Houdent C, Murat A, Schlumberger M, et al. (1995) RET mutations in exons 13 and 14 of FMTC patients. Oncogene 10:2415-2419
21. Boccia LM, Green JS, Joyce C, Eng C, Taylor SA, Mulligan LM (1997) Mutation of RET codon 768 is associated with the FMTC phenotype. Clin Genet 51:81-85
22. Smith DP, Houghton C, Ponder BA (1997) Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 15: 1213-1217
23. Gimm O, Marsh DJ. Andrew SD, Frilling A, Dahia PL, Mulligan LM, Zajac JD, Robinson BG, Eng C (1997) Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 82:3902-3904
24. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, et al. (1995) Activation of RET as a dominant transforming gene by eermline mutations of MEN2A and MEN2B. Science 267:381-383
25. Asai N, Iwashita T, Matsuyama M, Takahashi M (1995) Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 15: 1613-1619
26. Pasini A, Geneste O, Legrand P, Schlumberger M, Rossel M, Fournier L, Rudkin BB, Schuffenecker I, Lenoir GM, Billaud M (1997) Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain. Oncogene 15:393-402
27. Songyang Z, Carraway KL, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, Schlessinger J, Hubbard SR, Smith DP, Eng C, Lornezo MJ, Ponder BAJ, Mayer BJ, Cantley LC (1995) Catalytic specificity of protein tyrosine kinases is critical for selective signalling. Nature 373:536-539
28. Bongarzone I, Vigano E, Alberti L, Borrello MG, Pasini B, Greco A, Mondellini P, Smith DP, Ponder BA, Romeo G, Pierotti MA (1998) Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation. Oncogene 16:2295-2301
29. Eng C, Mulligan LM (1997) Mutation: of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease. Hum Mutat 9:97-109
30. Eng C, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, Thomas GA, Ponder BA (1996) Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 56:2167-2170
31. Gimm O, Neuberg DS, Marsh DJ, Dahia PLM, Hoane-Vu C, Raue F, Hinze R, Dralle H, Eng C (1999) Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. Oncogene (in press)
32. Wimg DG, Johnston CF, Anderson N, Sloan JM, Buchanan KD (1995) Over-expression of the tumour suppressor gene p53 is not implicated in neuroendocrine tumour carcinogenesis (comments). J Pathol 175:397-401
33. Herfarth KK, Wick MR, Marshall HN, Gartner E, Lum S, Moley JF (1997) Absence of TP53 alterations in pheochromocytomas and medullary thyroid carcinomas. Genes Chromosomes Cancer 20:24-29
34. Mulligan LM, Gardner E, Smith BA, Mathew CG, Ponder BA (1993) Genetic events in tumour initiation and progression in multiple endocrine neoplasia type 2. Genes Chromosomes Cancer 6: 166-177
35. Raue F, Kotzerke J, Reinwein D, Schroder S, Roher HD, Deckart H, Hofer R, Ritter M, Seif F, Buhr H, et al. (1993) Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Invest 71:7-12
36. Hinze R, Holzhausen HJ, Gimm O, Dralle H, Rath FW (1998) Primary hereditary medullary thyroid carcinoma-C-cell morphology and correlation with preoperative calcitonin levels. Virchows Arch 433:203-208
37. Telander RL, Moir CR (1994) Medullary thyroid carcinoma in children. Semin Pediatr Surg 3: 188-193
38. Gill JR, Reyes-Mugica M, Iyengar S, Kidd KK, Touloukian RJ, Smith C, Keller MS, Genel M (1996) Early presentation of metastatic medullary carcinoma in multiple endocrine neoplasia, type IIA: implications for therapy. J Pediatr 129:459-464
39. Collins BT, Cramer HM, Tabatowski K, Hearn S, Raminhos A, Lampe H (1995) Fine needle aspiration of medullary carcinoma of the thyroid. Cytomorphology, immunocytochemistry and electron microscopy. Acta Cytol 39:920-930
40. Lips CJM, Landsvater RM, Hoppener JWM, Geerdink RA, Blijham G, Jansen-Schillhorn van Veen JM, van Gils APG, de Witt MJ, Zewald RA, Berends MJH, Beemer FA, Brouwers-Smalbraak J, Jansen RPM, Ploos van Amstel HK, van Vroonhoven TJMV, Vroom TM (1994) Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 331:828-835
41. Henry JF, Denizot A, Puccini M, Gramatica L, Kvachenyuk A, Conte Devolx B, De Micco C (1998) Latent subclinical medullary thyroid carcinoma: diagnosis and treatment. World J Surg 22:752-757
42. Dralle H, Gimm O, Simon D, Frank-Raue K, Gortz G, Niederle B, Wahl RA, Koch B, Walgenbach S, Hampel R, Ritter MM, Spelsberg F, Heiss A, Hinze R, Hoppner W (1998) Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 22:744-751
43. Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L (1996) Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 77: 1556-1565
44. Bergholm U, Bergstrom R, Ekbom A (1997) Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer 79: 132-138
45. Gimm O, Ukkat J, Dralle H (1998) Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg 22:562-568
46. Marzano LA, Porcelli A, Biondi B, Lupoli G, Delrio P, Lombardi G, Zarrilli L (1995) Surgical management and follow-up of medullary thyroid carcinoma. J Surg Oncol 59: 162-168
47. Girelli ME, Dotto S, Nacamulli D, Piccolo M, De Vido D, Russo T, Bernante P, Pelizzo MR, Busnardo B (1994) Prognostic value of early postoperative calcitonin level in medullary thyroid carcinoma. Tumori 80: 113-117
48. Tisell LE, Hansson G, Jansson S, Salander H (1986) Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 99:60-66
49. Dralle H, Damm I, Scheumann GF, Kotzerke J, Kupsch E (1992) Frequency and significance of cervico-mediastinal lymph node metastases in medullary thyroid carcinoma: results of a compartment-oriented microdissection method. Henry Ford Hosp Med J 40:264-267
50. Buhr HJ, Kallinowski F, Raue F, Frank-Raue K, Herfarth C (1993) Microsurgical neck dissection for occultly metastasizing medullary thyroid carcinoma. Three-year results. Cancer 72:3685-3693
51. Moley JF, Wells SA, Dilley WG, Tisell LE (1993) Reoperation for recurrent or persistent medullary thyroid cancer. Surgery 114: 1090-1096
52. Dralle H, Scheumann GF, Kotzerke J, Brabant EG (1992) Surgical management of MEN 2. Recent Results Cancer Res 125: 167-195
53. Dralle H, Damm I, Scheumann GF, Kotzerke J, Kupsch E, Geerlings H, Pichlmayr R (1994) Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 24: 112-121
54. Moley JF (1995) Medullary thyroid cancer. Surg Clin North Am 75:405-420
55. Heshmati HM, Gharib H, van Heerden JA, Sizemore GW (1997) Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am JMed 103:60-69
56. Dralle H, Gimm O (1996) Lymph node excision in thyroid carcinoma. Chirurg 67:788-806
57. Gimm O, Dralle H (1997) Reoperation in metastasizing medullary thyroid carcinoma: is a tumor stage-oriented approach justified? Suraery 122: 1124-1131
58. Samaan NA, Schultz PN, Hickey RC (1988) Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 67:801-805
59. Wells SA, Jr, Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton SB, Ivanovich JL, DeBenedetti MK, Dilley WG, Moley JF, et al. (1994) Predictive DNA testing and prophylactic thyroid-ectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 220:237-250
60. Pacini F, Romei C, Miccoli P, Elisei R, Molinaro E, Mancusi F, Iacconi P, Basolo F, Martino E, Pinchera A (1995) Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. Surgery 118: 1031-1035
61. Decker RA, Geiger JD, Cox CE, Mackovjak M, Sarkar M, Peacock ML (1996) Prophylactic surgery for multiple endocrine neoplasia type IIa after genetic diagnosis: is parathyroid transplantation indicated? World J Surg 20:814-821
62. Telander RL, Zimmerman D, Sizemore GW, van Heerden JA, Grant CS (1989) Medullary carcinoma in children. Results of early detection and surgery. Arch Surg 124:841-843
63. Juweid M, Sharkey RM, Behr T, Swayne LC, Herskovic T, Pereira M, Rubin AD, Hanley D, Dunn R, Siegel J, Goldenberg DM (1996) Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies. J Nucl Med 37:905-911
64. Behr TM, Wulst E, Radetzky S, Blumenthal RD, Dunn RM, Gratz S, Rave-Frank M, Schmidberger H, Raue F, Becker W (1997) Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res 57:5309-5319
65. Nguyen TD, Chassard JL, Lagarde P, Cutuli B, Le Fur R, Reme-Saumon M, Prevost B, Panis X, Verrelle P, Chaplain G (1992) Results of postoperative radiation therapy in medullary carcinoma of the thyroid: a retrospective study by the French Federation of Cancer Institutes - the Radiotherapy Cooperative Group. Radiother Oncol 23: 1-5
66. Simpson WJ (1990) Radioiodine and radiotherapy in the management of thyroid cancers. Otolaryngol Clin North Am 23:509-521
67. Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE (1995) Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 71:363-365
68. Frank-Raue K, Bihl H, Dorr U, Buhr H, Ziegler R, Raue F (1995) Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol (Oxf) 42:31-37
69. Mahler C, Verhelst J, de Longueville M, Harris A (1990) Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol (Oxf) 33:261-269